Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5
This approval introduces a once-daily oral treatment option, offering greater flexibility for patients who require additional LDL cholesterol reduction despite receiving existing lipid-lowering therapies
The peer-reviewed findings will be presented on Saturday (June 13) at ENDO 2026, the Endocrine Society's annual meeting
doi: 10.1161/HYPERTENSIONAHA.119.14400 81 KamiyamaMUrushiharaMMorikawaTKonishiYImanishiMNishiyamaAet al
In the past year, many telehealth and digital health companies have jumped into the market, offering prescriptions for GLP-1s as part of an existing weight loss or chronic condition management program, or creating a new service line targeting obesity care
Trial populations and endpoints differ across the published studies, and results vary considerably from one person to the next
But with the obesity market still early in its global adoption curve, 18.9% growth looks conservative rather than ambitious
,type=downsize)
